Javier Álvarez (Spain)
Hospital Costa del Sol Paediatric DepartmentAuthor Of 1 Presentation
MODELED IMPACT OF NIRSEVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) AMONG SPANISH INFANTS EXPERIENCING THEIR FIRST RSV SEASON
Abstract
Backgrounds:
Respiratory syncytial virus (RSV), a leading cause of viral lower respiratory tract illness (LRTI) in young children, is associated with significant morbidity, especially during their first year of life. Nirsevimab is an investigational long-acting antibody developed to prevent medically attended RSV-LRTI (RSV MALRTI). The objective of this work was to explore public health and economic impact of a strategy that immunizes all Spanish infants experiencing their first RSV season with nirsevimab compared to current standard of practice (SoP).
Methods
A static decision analytic model was developed that tracks the whole Spanish infant cohort, by month of birth, during their first RSV season and considers the different possible RSV-related health outcomes and their associated costs. Impact of nirsevimab was modelled, considering an efficacy of 79.5% in term and preterm infants (based on a pooled analysis from Phase IIb [preterm infants] and MELODY Phase III [term infants] studies), and non-inferiority in palivizumab-eligible infants. An immediate onset of protection, and 5 months of protection were assumed.
Results:
The model estimated these cases avoided: 8,201 hospitalisations, including 872 intensive care cases, 24,420 emergency department visits, as well as 93,209 primary care visits and 9 deaths over one season. The associated annual economic savings were estimated at €29.8 million in healthcare costs and €2.3 million in lost productivity, without considering the cost of preventive passive immunization alternatives (Table 1). The largest reduction in events and costs was seen in preterm and term infants. Additionally, reduction in heath events provided by nirsevimab impacted infants born out of season in a 2-to-1 ratio compared to infants born in season.
Conclusions/Learning Points:
Immunization of all infants experiencing their first RSV season with nirsevimab is likely to result in thousands of RSV cases avoided versus current SoP.
This study was funded by Sanofi Pasteur, Spain